Products for Research Use Only
RegisterLogin

IPH5201

CAT: 0804-HY-P991444Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P991444Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control.
UNSPSC
12352203
Target
NTPDase
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
I[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5]
References & Citations
[1]Barlesi F, et al. 1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE) [J]. Annals of Oncology, 2023, 34: S744.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported

Related Products

CatalogName
HY-P991443IPH5301

Alternative Products

CatalogName
T9901A-1061-01IPH5201
ICH5218-500mgIPH5201 Biosimilar - Research Grade
PTX26434Anti-Human CD39/ENTPD1 Monoclonal Antibody (IPH5201)
DHE74007Research Grade Anti-Human CD39/ENTPD1 Antibody (IPH5201)
A136855Anti-CD39/ENTPD1 Antibody (IPH5201) Biosimilar (Monoclonal, IgG1)

Popular Products